Background: The prevalence of azole resistance in Aspergillus fumigatus is uncertain in Australia. Azole exposure may select for resistance. We investigated the frequency of azole resistance in a large number of clinical and environmental isolates.
Methods: A. fumigatus isolates [148 human, 21 animal and 185 environmental strains from air (n " 6) and azole-exposed (n " 64) or azole-naive (n " 115) environments] were screened for azole resistance using the VIPcheck TM system. MICs were determined using the Sensititre TM YeastOne YO10 assay. Sequencing of the Aspergillus cyp51A gene and promoter region was performed for azole-resistant isolates, and cyp51A homology protein modelling undertaken.
Results: Non-WT MICs/MICs at the epidemiological cut-off value of one or more azoles were observed for 3/148 (2%) human isolates but not amongst animal, or environmental, isolates. All three isolates grew on at least one azole-supplemented well based on VIPcheck TM screening. For isolates 9 and 32, the itraconazole and posaconazole MICs were 1 mg/L (voriconazole MICs 0.12 mg/L); isolate 129 had itraconazole, posaconazole and voriconazole MICs of .16, 1 and 8 mg/L, respectively. Soil isolates from azole-exposed and azole-naive environments had similar geometric mean MICs of itraconazole, posaconazole and voriconazole (P . 0.05). A G54R mutation was identified in the isolates exhibiting itraconazole and posaconazole resistance, and the TR 34 /L98H mutation in the pan-azole-resistant isolate. cyp51A modelling predicted that the G54R mutation would prevent binding of itraconazole and posaconazole to the haem complex.
Conclusions: Azole resistance is uncommon in Australian clinical and environmental A. fumigatus isolates; further surveillance is indicated.
Introduction
Aspergillus fumigatus causes aspergillosis in humans and animals ranging from chronic forms to acute invasive aspergillosis (IA). IA, in particular, presents significant problems for haematological patients, with mortalities of .50%.
1,2 Antifungal triazoles are firstline agents for managing these infections and preventing fungal diseases in agriculture and construction. 3 The emergence of azoleresistant strains of A. fumigatus (ARAf) is thus concerning, being associated with treatment failure and resistance, and may be particularly relevant in haematology patients, many of whom have prior exposure to azoles.
2,4-6 Selection pressure for ARAf has also been linked to exposure to agricultural azole-based fungicides, the demethylation inhibitors (DMIs). [5] [6] [7] Major mechanisms of azole resistance in ARAf include SNPs in the A. fumigatus cyp51A gene, alone or combined with tandem repeats (TRs) in the promoter region. [8] [9] [10] The prevalence of ARAf varies with geographical region and is highest in Europe (3%-26%). 5, 8, 10 In Australia, while ARAf isolates have been identified, 11 their prevalence is uncertain. To better understand the burden of ARAf, we investigated the frequency of resistance to itraconazole, voriconazole and posaconazole among clinical and environmental A. fumigatus isolates.
Methods
Human isolates of A. fumigatus (n " 148) were obtained from culture collections at Westmead and Royal Hobart Hospitals from 2015 to 2017 (Table S1 , available as Supplementary data at JAC Online). Of these, 35 isolates were from patients with physician-ascribed IA using established criteria where appropriate (see Table S1 ). 12 Twenty-one animal isolates (School of Veterinary Science, University of Sydney, 2013-17; Table S1 ) and 185 environmental isolates from azole-naive (n " 115) or azole-exposed (n " 64) habitats and ambient air (n " 6) (2013-17; Table S2 ) were also studied.
For isolation of A. fumigatus, soil samples were stored at 4 C and processed within 1 week (method 1), 13 with 100 lL of soil suspension incubated at 45 C on malt extract agar containing chloramphenicol (MEASC). Early experiments showed that for azole-treated soils, A. fumigatus yields were low and samples were reprocessed using 'method 2' as previously described.
14 Briefly, two sets of 5% serial 1:10 dilutions of soil were analysed. One set was heat treated at 75 C for 30 min and 100 lL from each dilution was incubated at 37 C on MEASC for 21 days. Colonies were identified as A. fumigatus species complex by standard morphological methods. 15 Identity was confirmed as A. fumigatus sensu stricto by b-tubulin gene sequencing. 16 To screen for azole resistance, Aspergillus isolates were inoculated onto 4-well VIPcheck TM plates (Balis Laboratorium VOF, Boven Leeuwen, The Netherlands) with wells supplemented with itraconazole (4 mg/L), voriconazole (2 mg/L) or posaconazole (0.5 mg/L), or unsupplemented. 17 Isolates growing only in the control well were considered azole susceptible. Isolates that grew on any azole-containing well underwent re-examination and susceptibility testing using the Sensititre TM YeastOne YO10 system (TREK Diagnostics Systems Ltd, OH, USA). 18 Both Sensititre TM and VIPcheck TM testing was repeated for isolates that grew on azole-supplemented wells.
Susceptibility testing was performed on all human isolates and randomly selected animal (n " 11, 52%) and environmental (n " 41, 22%) isolates according to the manufacturer's instructions and following CLSI methodology (Third Edition: M38). 18 MICs or minimum effective concentrations (MECs) were read after 48 h of incubation and determined by visual inspection. Candida parapsilosis ATCC 22019 (GenBank reference NRRL Y-12969) was the quality control, and A. fumigatus ATCC 204305 (GenBank reference KC689329, KU729126 and KU897017) was the reference strain. 18 MICs or MECs were assessed using established criteria, with MICs read at 100% inhibition, i.e. no signs of visual growth. 18 Interpretative criteria based on epidemiological cut-off values (ECVs) were: for itraconazole and voriconazole, an MIC of 1 mg/L was WT and 2 mg/L was non-WT (NWT); and for posaconazole, an MIC of 0.25 mg/L was WT and .0.5 mg/L was NWT. 19, 20 Geometric mean (GM) MICs/MECs were calculated for WT isolates. Standard deviations and t-scores compared GM MICs for groups of isolates with significance set at P 0.05. For isolates with NWT MICs, the Aspergillus cyp51A gene and promoter region were amplified and sequenced. 21 Sequences were aligned with GenBank reference sequence AF222068. 21 The A. fumigatus cyp51A sequence AF338659 22 was obtained from the universal protein resource (http://www.uniprot.org). Homology modelling was inter alia cyp51B-based with the crystal structure of A. fumigatus cyp51B retrieved from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (http://www.rcsb.org) as it returned the highest sequence identity and BLAST score (identification no. 5FRB: resolution 2.99 Å , max score 660, total score 660, query cover 92%, identity 65%). Of five homology models of the cyp51A gene built using Schrödinger's Prime, 23 the best model (data not shown) was prepared for molecular docking (see below).
The single-residue mutation G54R was tested with 2D structures of itraconazole, posaconazole and voriconazole and drawn (Schrödinger Release 2017-3; LigPrep LLC, New York). Docking of the three triazoles was carried out via Glide with extra precision (XP), 24 
Results

Environmental sampling
In addition to culture collection isolates included in this study [ambient air (n " 6) and soil (n " 20)] a further 159 A. fumigatus environmental cultures were isolated from soil. Method 1 yielded 91 A. fumigatus isolates from azole-naive soils (n " 90) and azoleexposed soils (n " 1). Method 2 yielded an additional 68 isolates from azole-naive soils (n " 5) and azole-exposed soils (n " 63).
Resistance screening
Five isolates (one avian and four from azole-exposed soil) grew on the itraconazole-containing well of the VIPcheck TM plate. Of 148 human isolates, isolate 129 grew on all azole-supplemented wells, and isolates 9 and 32 grew on posaconazole-and itraconazole-containing wells. Isolates 32 and 129 were from patients who had received prior fluconazole as antifungal prophylaxis during the preceding 6 month period, whilst isolate 9 was from an azole-naive patient. All three patients had invasive pulmonary aspergillosis. 12 Tables S1 and S2 for cyp51A sequencing and modelling cyp51A mutations were identified in the three isolates with NWT MICs or MICs at the ECV (see Table S1 ) (GenBank accession numbers MG687254-MG687257). Isolates 9 and 32 had SNPs present at nucleotide position 160 (GGG to AGG and CGG, respectively), resulting in a G54R substitution. Isolate 32 had another SNP at nucleotide position 744 (AAT to AAA), resulting in N248K. Isolate 129 carried a TR 34 /L98H mutation at nucleotide position 323.
Susceptibility testing
Modelling G54R indicated that replacing the short side-chain glycine (G) with arginine (R) allowed the formation of hydrogen bonds with T50 and S493, which closes off binding channel access (Figure 1 ). This closed conformation stabilized the model by 84.47 kcal/mol with high likelihood that the large triazole structures (itraconazole and posaconazole but not voriconazole) would be prevented from entering the channel.
Discussion
This large study found isolates with NWT MICs to be uncommon in Australian human clinical isolates (2.0%), and at the lower end of that seen globally (0%-26%), contrasting particularly with that in the Netherlands. 5, 8, 10 Of note, ARAf was absent amongst animal isolates. These data suggest that treatment guidelines currently recommending azoles as preferred therapy for IA remain appropriate in Australia. 3 Also notable was the apparent absence of ARAf in the environment, including azole-exposed habitats. Environmental studies (112) c DMIs used on azole-exposed soil isolates included cyproconazole (n " 3), myclobutanil (n " 4), tebuconazole and epoxiconazole (n " 10), tebuconazole and myclobutanil (n " 1), tebuconazole and penconazole (n " 3), and tetraconazole and myclobutanil (n " 2).
Azole-resistant Aspergillus fumigatus in Australia JAC have reported a broad range of prevalence of ARAf (0%-91%), with the highest prevalence in the Netherlands, where most resistant isolates carry the TR 34 /L98H mechanism. 7 The implications of our results for agricultural practice, although uncertain, raise questions regarding the impact of different agricultural practices between Australia and Europe including percentage of crop area treated, number and amount of applications/crop, and type and rotation of DMIs used. Composts, which have yielded a high percentage of environmental ARAf in Europe, 25 are not used in broadacre farming in Australia. Additionally, compared with Western Europe, the Australian climate has prolonged periods of dryness or drought, where the need for DMIs is greatly reduced. In Australia, the most commonly used azole fungicides for grape crops include difenoconazole, myclobutanil, penconazole, tebuconazole and tetraconazole and for grain crops cyproconazole, epoxiconazole, propiconazole, prothioconazole and tebuconazole. 26 Azole fungicide and medical practices of different locations worldwide should be compared to further our understanding of the variation in ARAf prevalence rates between regions.
The agar-based VIPcheck TM screening test is well established to have sufficiently high sensitivity and specificity for predicting azole resistance. 27 In the present study, the test proved useful in screening for resistance with no false 'susceptible' results; all isolates with NWT MICs or with MICs at the ECV were observed to grow on the plates. The VIPcheck TM plates overcalled 'resistance' for five isolates (5/8 isolates, specificity 97.5%). This is reasonable for a screening test which must have a high negative predictive value. As the VIPcheck TM test does not measure MICs, all isolates that grow on azole-supplemented agar should be tested for antifungal susceptibility.
The G54R mutation, identified here in two isolates, is known to confer differential azole resistance in A. fumigatus.
9 One of our isolates with the G54R mutation had a second mutation leading to amino acid substitution N248K; however, this also occurs in azolesusceptible A. fumigatus isolates with no documented link to resistance. 9 Pan-resistance in isolate 129 was through the TR 34 /L98H mutation, consistent with existing literature. 10 Of note, both TR 34 /L98H and G54R mutations have been linked to environmental acquisition, 7, 10 and were identified previously in three other Australian clinical isolates. 11 Our homology modelling results using a cyp51B A. fumigatus model are consistent with previous observations in non-Aspergillus cyp51A models that the G54R mutation can prevent docking of the long-tailed azoles itraconazole and posaconazole but not of the more compact voriconazole molecule. 28 Recovery of A. fumigatus from soil found that method 2, which uses heat-shock to inactivate asexual spores, gave a higher yield of isolates from azole-treated soils. Although no ARAf was found, the survival of sexual spores in azole-treated soil could serve as a potential reservoir for resistance development; in the laboratory setting, sexual reproduction has been implicated in the development of cyp51A-mediated azole resistance. 25 A limitation of the present study was that clinical data were not collected. This prevented more precise determination of ARAf incidence amongst different groups of azole-exposed or azole-naive patients. About half of the cystic fibrosis patients in the Centre for Infectious Diseases and Microbiology Laboratory Services receive intermittent azole therapy (usually itraconazole) (S. C.-A. Chen, unpublished data). Other isolates were recovered from disparate groups of patients with unknown azole exposure. Whilst it is possible that the low prevalence observed is related to potential inhomogeneity in the patient population, the fact that we only observed three 'azole-resistant' isolates would limit any statistically meaningful data. We acknowledge the importance of prospective studies to investigate azole resistance amongst specific patient groups.
In conclusion, ARAf appears to be uncommon in Australia, which indicates that the preferred therapy for aspergillosis does not need to be changed. However, continued surveillance is warranted to pre-empt the emergence of ARAf strains and to inform management strategies. 
